TScan Therapeutics appoints Chrystal U. Louis as CMO; Dr. Debora Barton departs

TScan Therapeutics, Inc.

Chrystal U. Louis, M.D., M.P.H., named Chief Medical Officer effective April 8, 2024.
Dr. Louis brings 20+ years of hematology/oncology drug development and cell therapy experience.
Outgoing CMO Dr. Debora Barton departing for personal reasons; will continue as consultant.
Dr. Barton joined TScan in July 2022; contributed to heme program and solid tumor initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.